

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

July 24, 2015

Boston Scientific Ms. Anna Deraney Regulatory Affairs Specialist One Scimed Place Maple Grove, Minnesota 55311

Re: K143193

Trade/Device Name: Symmetry and Symmetry Stiff Shaft Balloon Dilatation Catheters Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: LIT Dated: June 5, 2015 Received: June 8, 2015

Dear Ms. Deraney:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801and Part 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part

807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<u>http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</u> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Kenneth J. Cavanaugh -S

for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

EF	PSC Publishing Services (301) 443-6740	Page 1 of 1	FORM FDA 3881 (8/14)
	1 to respond to, a collection of 3 number."	ot conduct or sponsor, and a person is not required to respondinformation unless it displays a currently valid OMB number."	"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
	9 hours per response, including the ain the data needed and complete rden estimate or any other aspect n, to: rices	f information is estimated to average 79 ho existing data sources, gather and maintain the tion. Send comments regarding this burden ng suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov	The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
	eduction Act of 1995. EMAIL ADDRESS BELOW.*	This section applies only to requirements of the Paperwork Reduction Act of 1995. DT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS B	This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
I	EDED.	CONTINUE ON A SEPARATE PAGE IF NEEDED.	CONTINUE C
I.	Over-The-Counter Use (21 CFR 801 Subpart C)		Type of Use (Select one or both, as applicable)
	bheral vasculature.	oral or renal vessels in the peri	Angioplasty of narrowed or obstructed iliac, femoral or renal vessels in the peripheral vasculature.
	d for Percutaneous Transluminal	Dilatation Catheters are indicate	Indications for Use (<i>Describe</i>) Symmetry TM and Symmetry Stiff Shaft Balloon Dilatation Catheters are indicated for Percutaneous Transluminal
1		ation Catheter	Device Name Symmetry TM and Symmetry Stiff Shaft Balloon Dilatation Catheter
			510(k) Number <i>(if known)</i> K143193
	Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.	HUMAN SERVICES istration r Use	DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use
1			

510k Summary

Per 21 CFR §807.92

Common or Usual Name	Balloon Dilatation Catheter		
Trade Name(s)	Boston Scientific Sym Dilatation Catheter	metry [™] and Symmetry Stiff Shaft Balloon	
Product Code	LIT – Catheter, Angiop	blasty, Peripheral, Transluminal	
Classification of Device		atation catheters and accessories have been levices according to 21 CFR 870.1250 – er.	
Submitter's Name and Address	Boston Scientific Corporation One Scimed Place Maple Grove, MN 55311-1566		
Contact Name and Information	Anna Deraney Regulatory Affairs Specialist Phone: 763-494-1683 Fax: 763-494-2222 Email: anna.deraney@bsci.com		
Section 514 of the Act Performance Standards	Currently no FDA mandated or voluntary performance standards exist for this device.		
Establishment Registration Numbers	Owner /Operator:	Boston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752	
	Manufacturing Facility:	Boston Scientific Ireland Ltd. (BSIL)	
		Ballybrit Business Park	
		Galway, Ireland	
		ERN: 9681260	
	Sterilization Facilities:	Synergy Health Ireland Limited IDA Business & Technology Park Tullamore, County Offaly, Ireland	
Predicate Devices	Symmetry Balloon Dilatation Catheter K060959 cleared April 12, 2006.		

Intended Use/ Indications for Use	Symmetry [™] and Symmetry Stiff Shaft Balloon Dilatation Catheters are indicated for Percutaneous Transluminal Angioplasty of narrowed or obstructed iliac, femoral, or renal vessels in the peripheral vasculature.	
Comparison of Required Technological Characteristics	The proposed Symmetry Balloon Dilatation Catheter is substantially equivalent to the existing Symmetry Balloon Dilatation Catheter cleared by FDA under premarket notification K060959 (April 12, 2006). Symmetry has the same intended use, scientific technology, design, materials (with the exception of the Pebax resin used in the shaft), sterilization method, and packaging materials as the applicable predicate device.	
	The vendor is discontinuing the supply of the current Pebax resin, which is used in the shaft of the device; therefore a new resin is being supplied.	
Summary of Non- Clinical Test Summary	Bench testing and biocompatibility testing were performed to support a determination of substantial equivalence. The results of these tests provide reasonable assurance that the proposed device has been designed and tested to assure conformance to the requirements for its intended use. No new safety or performance issues were raised during the device testing.	
Conclusion	Based on the indications for use, technological characteristics, and safety and performance testing, the proposed Symmetry Balloon Dilatation Catheter has been shown to be appropriate for its intended use and is considered to be substantially equivalent to the Symmetry Balloon Dilatation Catheter (K060959).	